Michael Andreeff Selected Research

Sorafenib (BAY 43-9006)

11/2020	Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
1/2020	First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations.
1/2019	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
10/2018	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
1/2018	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
4/2016	Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
5/2014	Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
6/2013	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
2/2013	Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
12/2011	Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Andreeff Research Topics

Disease

174	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 01/2002
123	Neoplasms (Cancer) 12/2023 - 01/2002
110	Leukemia 11/2023 - 02/2002
20	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 06/2002
17	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2024 - 04/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2002
17	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2019 - 06/2002
16	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2002
16	Hematologic Neoplasms (Hematological Malignancy) 03/2021 - 01/2002
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
14	Hypoxia (Hypoxemia) 01/2023 - 08/2009
11	Acute Promyelocytic Leukemia 01/2022 - 03/2004
10	Lymphoma (Lymphomas) 01/2015 - 10/2004
9	Carcinogenesis 01/2022 - 09/2003
8	Philadelphia Chromosome 10/2011 - 04/2002
6	Blast Crisis (Blast Phase) 10/2015 - 02/2006
5	Inflammation (Inflammations) 10/2019 - 03/2006
5	Myeloid Leukemia (Leukemia, Myelocytic) 01/2017 - 01/2002
5	Glioma (Gliomas) 04/2013 - 04/2005
5	Mitochondrial Diseases (Mitochondrial Disease) 05/2008 - 12/2005
4	Disease Progression 01/2022 - 06/2008
4	AIDS-Related Complex (ARC) 01/2019 - 01/2011
4	Residual Neoplasm 01/2018 - 01/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010 - 10/2002
3	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 09/2002
3	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 06/2002
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 10/2018

Drug/Important Bio-Agent (IBA)

67	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2002
31	venetoclaxIBA 04/2024 - 03/2014
28	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 04/2002
20	TriterpenesIBA 11/2014 - 01/2002
15	bardoxoloneIBA 04/2012 - 01/2002
14	Phosphotransferases (Kinase)IBA 02/2023 - 06/2003
14	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 02/2008
13	LigandsIBA 01/2023 - 07/2002
12	bardoxolone methylIBA 11/2014 - 01/2002
11	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 06/2013
11	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 07/2002
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2018 - 05/2002
10	CaspasesIBA 11/2014 - 12/2002
10	SurvivinIBA 08/2013 - 09/2003
10	AcidsIBA 11/2007 - 09/2003
9	fms-Like Tyrosine Kinase 3IBA 01/2023 - 04/2006
9	Tyrosine Kinase InhibitorsIBA 04/2022 - 06/2003
9	Oxygen (Dioxygen)IBA 10/2021 - 07/2008
9	ABT-737IBA 09/2021 - 11/2006
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 06/2006
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 02/2006
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
8	CytokinesIBA 01/2020 - 09/2002
7	EnzymesIBA 01/2023 - 01/2009
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 03/2009
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 04/2005
7	bcr-abl Fusion ProteinsIBA 01/2016 - 07/2002
7	fludarabineIBA 07/2015 - 04/2002
6	Decitabine FDA Link 01/2022 - 08/2003
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 03/2006
6	MicroRNAs (MicroRNA)IBA 01/2018 - 03/2008
6	Messenger RNA (mRNA)IBA 01/2018 - 06/2002
6	nutlin 3IBA 01/2017 - 08/2006
5	MethyltransferasesIBA 01/2023 - 06/2009
5	NF-kappa B (NF-kB)IBA 01/2022 - 01/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 06/2009
5	selinexorIBA 11/2020 - 01/2015
5	Adenosine Triphosphate (ATP)IBA 01/2013 - 12/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2012 - 08/2005
5	EstersIBA 12/2010 - 01/2002
5	PPAR gammaIBA 06/2010 - 07/2002
4	Drug CombinationsIBA 01/2023 - 05/2014
4	NucleophosminIBA 01/2023 - 12/2013
4	Glutathione (Reduced Glutathione)IBA 01/2023 - 10/2005
4	Galectin 3 (LGALS3)IBA 06/2019 - 04/2016
4	Rituximab (Mabthera)FDA Link 01/2019 - 05/2003
4	CateninsIBA 01/2019 - 04/2014
4	ChemokinesIBA 04/2016 - 12/2006
4	ProdrugsIBA 04/2016 - 01/2011
4	Bortezomib (Velcade)FDA Link 02/2016 - 10/2003
4	Cyclin D1IBA 01/2015 - 09/2003
4	Monoclonal AntibodiesIBA 03/2014 - 06/2005
4	Caspase 8 (Caspase-8)IBA 02/2014 - 05/2005
4	Antisense OligonucleotidesIBA 08/2013 - 02/2009
4	Chemokine CXCL12IBA 01/2013 - 04/2005
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2012 - 04/2002
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2010 - 04/2005
4	Mitogen-Activated Protein KinasesIBA 03/2010 - 05/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008 - 09/2002
4	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 03/2004
3	snake venom protein C activatorIBA 10/2023 - 01/2019
3	DS-5272IBA 03/2023 - 01/2020
3	Aurora KinasesIBA 02/2023 - 10/2008
3	Lysine (L-Lysine)FDA Link 01/2023 - 01/2021
3	Radioisotopes (Radionuclides)IBA 02/2022 - 01/2018
3	GD2 gangliosideIBA 01/2022 - 06/2012

Therapy/Procedure

96	Therapeutics 01/2024 - 04/2002
46	Drug Therapy (Chemotherapy) 01/2024 - 03/2003
5	Induction Chemotherapy 01/2022 - 03/2003
4	Transplantation 01/2022 - 01/2012
4	Radiotherapy 01/2021 - 08/2004
4	Stem Cell Transplantation 01/2018 - 12/2011
3	Immunotherapy 01/2022 - 04/2003